person
use
mass
reproduc
permiss
mayo
clinic
proceed
estim
million
peopl
live
hiv
howev
recent
global
figur
indic
epidem
begin
slow
perhap
revers
cours
hiv
incid
hivrel
death
decreas
nearli
worldwid
declin
attribut
part
access
antiretrovir
therapi
million
peopl
receiv
antiretrovir
therapi
global
tuberculosi
tb
continu
account
substanti
burden
diseas
million
hivposit
incid
case
million
preval
case
million
death
number
case
multidrugresist
tb
estim
juli
countri
territori
report
least
case
extens
drugresist
tb
intens
effort
reduc
global
burden
tb
way
cornerston
effort
access
qualiti
diagnosi
treatment
although
littl
progress
made
develop
new
antitb
drug
scaleup
intens
effort
improv
tb
care
control
global
result
million
live
save
introduct
newer
diagnost
modal
includ
autom
molecular
test
use
resourcelimit
set
burden
tb
highest
gener
great
optim
excit
mani
infect
becom
increasingli
difficult
treat
emerg
resist
commonli
use
antibiot
bacteria
develop
resist
respons
select
pressur
exert
inappropri
use
antibiot
mutat
confer
resist
may
pass
bacteria
speci
well
differ
speci
genera
hospitalacquir
antibioticresist
infect
estim
caus
death
unit
state
substanti
direct
indirect
econom
cost
countri
antibioticresist
infect
caus
varieti
organ
includ
methicillinresist
staphylococcu
aureu
penicillinintroduct
symposium
antimicrobi
therapi
n
issu
mayo
clinic
proceed
journal
reader
discov
first
articl
constitut
new
symposium
antimicrobi
therapi
articl
publish
sequenti
monthli
issu
journal
end
new
symposium
publish
part
reader
request
address
antimicrobi
drug
done
proceed
symposium
antimicrobi
agent
publish
octob
februari
new
symposium
arriv
import
time
infecti
diseas
manag
worldwid
past
decad
seen
unpreced
wave
new
old
infect
thrust
public
attent
time
number
emerg
reemerg
infecti
diseas
substanti
increas
emerg
infect
infect
appear
first
time
popul
wherea
reemerg
infect
known
infect
reappear
declin
incid
extend
geograph
impact
exampl
includ
pandem
influenza
viru
avian
influenza
viru
sever
acut
respiratori
syndrom
sar
west
nile
viru
infect
ehrlichiosi
featur
current
emerg
reemerg
infect
diseas
first
appear
one
geograph
locat
travers
contin
affect
million
peopl
within
short
period
first
report
mexico
spring
pandem
influenza
viru
infect
note
almost
countri
world
march
result
nearli
death
month
sar
spread
china
countri
affect
peopl
caus
death
human
immunodefici
viru
hiv
epidem
continu
affect
commun
worldwid
end
person
use
mass
reproduc
permiss
mayo
clinic
proceed
resist
pneumococci
vancomycinresist
enterococci
resist
gramneg
bacteria
eg
klebsiella
pneumonia
acinetobact
baumannii
pseudomona
aeruginosa
extendedspectrum
bacteria
eg
escherichia
coli
enterobact
speci
reason
epidem
antibiot
resist
among
bacteria
includ
poor
infect
control
practic
injudici
use
antibiot
human
medicin
injudici
use
antibiot
agricultur
problem
aggrav
lack
robust
antibiot
drugdevelop
pipelin
advanc
cancer
chemotherapi
transplant
result
increas
number
peopl
compromis
immun
well
increas
use
invas
procedur
widespectrum
antibiot
contribut
increas
incid
invas
fungal
infect
although
progress
made
develop
new
diagnost
assay
new
antifung
drug
remain
wholli
inadequ
optim
treatment
strategi
mani
invas
fungal
infect
remain
defin
mayo
clinic
proceed
editori
board
select
topic
symposium
antimicrobi
therapi
think
relev
practic
valu
gener
internist
clinician
first
articl
leekha
et
al
discuss
gener
principl
antimicrobi
therapi
dispens
pearl
infecti
diseas
practic
difficult
find
singl
public
subsequ
articl
address
varieti
infecti
diseaserel
topic
rang
pharmacolog
antimicrobi
agent
current
concept
manag
variou
infect
includ
bacteri
fungal
viral
mycobacteri
parasit
infect
topic
address
symposium
also
includ
laboratori
test
guid
antimicrobi
therapi
antibiot
prophylaxi
current
concept
outpati
antibiot
therapi
articl
author
expert
subject
matter
previou
symposia
publish
mayo
clinic
proceed
articl
symposium
antimicrobi
therapi
appear
journal
compil
book
hope
serv
valuabl
resourc
practic
clinician
zelalem
temesgen
md
divis
infecti
diseas
mayo
clinic
rochest
mn
